NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

全球再生醫學市場的分析和預測:幹細胞/組織工程/生物銀行/ CAR-T行業

Global Regenerative Medicine Market Analysis & Forecast to 2025: Stem Cells, Tissue Engineering, BioBanking & CAR-T Industries

出版商 Kelly Scientific Publications 商品編碼 959723
出版日期 內容資訊 英文 700 Pages
訂單完成後即時交付
價格
全球再生醫學市場的分析和預測:幹細胞/組織工程/生物銀行/ CAR-T行業 Global Regenerative Medicine Market Analysis & Forecast to 2025: Stem Cells, Tissue Engineering, BioBanking & CAR-T Industries
出版日期: 2020年09月07日內容資訊: 英文 700 Pages
簡介

全球再生醫學市場預計將從2019年的350億美元增長到2025年的1240億美元,在此期間的複合年增長率預計為23.3%。

本報告調查了全球再生醫學市場,提供了市場規模,細分分析(幹細胞/組織工程/生物銀行/CAR-T),主要公司和臨床試驗的全面概述。我們正在分析治療的可能性。

目錄

第1章報告摘要

  • 報告目的
  • 執行摘要
  • 本報告回答的主要問題
  • 數據來源和研究方法

第2章簡介

  • 古登先生和山中先生共同獲得諾貝爾獎
  • 幹細胞臨床試驗:從2010年開始
  • 幹細胞類型
  • 成人(組織)幹細胞
  • 多能幹細胞
  • 體細胞核移植(SCNT)
  • 人造多能幹細胞(iPSC)
  • 間質細胞
    • 骨髓基質乾細胞
    • MSC分離,標記特異性,功能特性
    • 氧氣濃度和MSC培養
    • 定義MSC的方法
    • MSC分化的可能性
    • MSC的治療潛力
    • 膜幹細胞與慢性疾病
    • MSC與肌萎縮性側索硬化
    • MSC和帕金森氏病
    • MSC和阿爾茨海默氏病
    • MSC和類風濕關節炎
    • MSC和1型糖尿病
    • MSC與心血管疾病
  • 造血幹細胞和前體細胞
    • 體內造血幹細胞測定
    • 造血幹細胞和前體細胞的體外測定
    • 造血幹細胞與前體細胞的分離
    • 造血細胞的培養
    • 造血細胞的治療用途
  • 臍帶乾細胞
  • 心臟幹細胞
    • 心臟幹細胞的最新研究
  • 乳房乾細胞
    • 乳幹細胞的定義
    • 模型系統對乾細胞鑑定的影響
    • 乳腺癌幹細胞
  • 神經乾細胞
    • 神經乾細胞的鑑定
    • 神經乾細胞在體內的功能
    • 神經乾細胞培養系統
    • 神經乾細胞分離策略
    • 腦腫瘤幹細胞
    • 神經乾細胞的最新研究
  • 幹細胞在視網膜修復中的應用
    • 胚胎幹細胞作為視網膜治療劑
    • 誘導多能幹細胞作為視網膜治療劑
    • 脂肪衍生間充質乾細胞作為視網膜治療劑
  • 肝幹細胞
  • 腸幹細胞
  • 胰腺幹細胞
  • 表皮幹細胞

第3章幹細胞和臨床試驗

  • 簡介
  • 多能幹細胞
  • 邊緣幹細胞
  • 神經乾細胞
  • 內皮幹細胞或前體細胞
  • 放置幹細胞
  • 幹細胞臨床試驗為何失敗?
  • 幹細胞測試的未來是什麼?
  • 最先進的干細胞臨床試驗
  • Ocata Therapeutics:當今的幹細胞實驗
  • CHA Biotech:當今的幹細胞實驗
  • Pfizer :當今的幹細胞實驗
  • GSK :當今的幹細胞實驗
  • Bayer :當今的幹細胞實驗
  • Mesoblast International :當今的幹細胞實驗
  • Millennium Pharmaceutical Current Stem Cell Trial
  • AstraZeneca :當今的幹細胞實驗
  • Merck :當今的幹細胞實驗
  • Chimerix :當今的幹細胞實驗
  • Eisai :當今的幹細胞實驗
  • SanBio :當今的幹細胞實驗
  • Celgene :當今的幹細胞實驗
  • StemCells :當今的幹細胞實驗
  • Genzyme (Sanofi) :當今的幹細胞實驗
  • Teva :當今的幹細胞實驗
  • MedImmune :當今的幹細胞實驗
  • Janssen :當今的幹細胞實驗
  • Seattle Genetics :當今的幹細胞實驗
  • Baxter Healthcare :當今的幹細胞實驗
  • InCyte Corp :當今的幹細胞實驗

第4章幹細胞,破壞性技術,藥物發現和毒性測試

  • 簡介
  • 案例研究:Genentech和乾細胞技術
  • 3D球形培養系統
  • 幹細胞和高通量篩選
    • 胚胎幹細胞
    • 成年幹細胞
    • 市場機遇與挑戰
  • 幹細胞的遺傳不穩定性
  • 全面的體外漿液性心律失常測定(CiPA)和心肌細胞
  • 結合精確基因組編輯(PGE)和iPSC
  • 幹細胞及毒性試驗
    • 肝毒性和iPSC
    • 心臟毒性和iPSC
    • 神經毒性和iPSC
  • 幹細胞疾病模型
  • 人類疾病特有的表型定義
    • 用於疾病建模的分子表型
    • 用於疾病建模的細胞表型
    • 用於疾病建模的生理表型
    • 帕金森氏病
    • 阿爾茨海默氏病
    • 肌萎縮性側索硬化
    • 亨廷頓舞蹈病
    • 脊髓肌肉萎縮
    • 唐氏病
    • 囊性纖維化
    • 大腸癌
  • 幹細胞來源的細胞和組織在藥物篩選中的優勢

第5章幹細胞生物標記物

  • 多能幹細胞生物標誌物
  • 膜幹細胞生物標誌物
  • 神經乾細胞生物標誌物
  • 造血幹細胞生物標誌物

第6章幹細胞產品的製造

  • 幹細胞產品製造策略
  • 幹細胞產品的生物過程經濟學
  • 資本投資
  • 產品價格
  • 經濟動力和生物工藝策略
  • 使用平面技術擴展和區分hPSC
  • 使用3D文化的hPSC擴展
  • 微載體系統
  • 粘性懸浮
  • 基於生物反應器的分化策略
  • 整合的hPSC生物過程策略
  • GMP調節和乾細胞產品

第7章投資和融資

  • 投資者希望從細胞和基因治療公司獲得什麼?
  • 什麼是好的投資?
  • 哪種類型的公司不接受投資?
  • 世界基金
  • 對細胞和基因療法的未來投資
  • 2018年最有前途的細胞和遺傳公司是哪些?
  • 考慮投資於細胞和基因治療公司

第8章到2025年再生醫學市場分析與預測

  • 市場概況
  • 世界頻率分析
  • 再生醫學經濟學
  • 再生療法市場的應用和機會
    • 神經系統疾病
    • 自身免疫性疾病
    • 心血管疾病
    • 糖尿病
    • 肌肉骨骼疾病
    • 眼疾
    • 骨科疾病
    • 傷口癒合
  • 全球財務狀況
  • 再生醫學臨床試驗統計
  • 預測再生醫學市場
  • 再生醫學的區域分析和預測
  • 企業再生醫學地理位置
  • 企業再生醫學技術細分
  • 商業上可獲得的再生醫療產品
  • 再生醫學的重大里程碑

第9章幹細胞市場分析與預測

  • 自體和同種異體細胞的市場分析
  • 區域幹細胞市場
    • 北美
    • 亞太地區
    • 歐洲
  • 按治療適應症預測幹細胞市場
    • 骨科/肌肉骨骼幹細胞二級市場
    • 癌症幹細胞二級市場
    • 心血管/血管幹細胞二級市場分析
    • 傷口癒合幹細胞二級市場分析
    • 皮膚幹細胞二級市場分析
    • 眼乾細胞二級市場預測
  • 幹細胞試劑市場趨勢

第10章組織工程市場分析與預測

  • 區域分析和預測
    • 北美
    • 歐洲
    • 亞太地區
  • 區域分析:公司份額
  • 組織工程學臨床指徵的分析和預測
    • 骨科和肌肉骨骼
    • 腫瘤科
    • 心血管和血管
    • 皮膚科
    • 口腔和牙科

第11章生物銀行市場分析

  • 全世界臍帶血庫數量不斷增加
  • 全球生物銀行公司的行業分析和細分
  • 同種異體與自體移植的頻率
  • 生物銀行市場分析與預測
  • 世界主要公司

第12章,全球再生醫學市場的准入和挑戰

  • 美國再生醫學市場
  • 日本再生醫學
    • 金融投資
    • 非常規企業對再生醫學的投資
  • 中國的再生醫學
  • 韓國再生醫學

第13章細胞和CAR T治療

  • 免疫療法中與細胞療法和嵌合抗原受體T細胞有關的挑戰
    • 迄今為止CD19 CAR-T細胞的臨床狀況
    • CAR T細胞發育的臨床和監管挑戰
    • 與CAR-T開發有關的主要法規問題
    • Juno,Novartis,Kite的CAR-T產品概述
    • CD19指示的所有臨床試驗中的毒性與毒性
    • 如何控制CAR-T治療的毒性
  • 免疫療法法規,包括美國的過繼細胞療法(CAR-T和TCR)免疫療法法規
    • 生物製品評估和研究中心(CBER)
    • 合規性和監控
    • FDA免疫療法的其他資源
    • 細胞,組織和基因療法諮詢委員會
    • FDA消費者部門(CBER)聯繫信息
    • FDA免疫療法法規
    • 案例研究:卵巢癌免疫療法的法規
    • 免疫療法的研究設計注意事項
    • 制定與免疫相關的反應標準(irRC)和針對免疫療法的臨床終點
  • 關於細胞療法和免疫療法的日本法規
    • PMDA與細胞療法和免疫療法
    • 提高細胞療法和免疫療法法規審查的效率
    • 先行者評論分配系統
    • 修訂後的抗腫瘤藥臨床評估指南
    • PMDA中用於細胞和免疫療法的關鍵聯繫人
  • 歐洲法規以及細胞療法和免疫療法
    • 簡介
    • 歐洲,中東和非洲的細胞療法和免疫療法面臨的挑戰
    • EMA狀態以進行功效測試
    • EMA狀態,用於識別高反應,低反應或無反應
    • 免疫療法中與生物標誌物有關的挑戰
    • 免疫療法中與嵌合抗原受體T細胞有關的挑戰
    • 估計最佳截止參數
    • 歐盟批准的黑色素瘤免疫療法
    • EMA內部用於細胞和免疫療法的關鍵聯繫人
  • 免疫療法的製造
    • 簡介
    • 生成CAR修飾的T細胞
    • 哪個共同刺激和活動區域最適合使用?
    • 細胞培養基的優化
    • 慢病毒載體的生產
    • 整合CAR表達載體的檢測
    • 供體淋巴細胞注射程序
    • 體內共刺激和供體T細胞擴增
    • 給病人注射
    • 製造設備和生產免疫療法所需的設備
    • 良好的免疫療法(GMP)製造程序
    • 案例研究在GMP條件下生產慢病毒誘導的樹突狀細胞
    • 質量控制
    • 製藥事務
    • 製造業的主要挑戰
    • 細胞療法製造中的自動化
    • 自體細胞療法的生產規模擴大
  • 供應鏈與物流
    • 簡介
    • 案例研究:Juno Therapeutics
  • 價格和成本分析
    • 簡介
    • CAR T治療的市場評估
    • CAR T市場當前交易
  • CAR-T治療與實體瘤
    • 實體瘤的挑戰
    • 避免在腫瘤微環境中進行免疫抑制
    • 有希望的臨床試驗

第14章公司簡介

  • Astellas Institute for Regenerative Medicine (Ocata Therapeutics)
  • Athersys
  • Baxter International (Baxalta, Shire)
  • Caladrius Biosciences(NeoStem)
  • Cynata Therapeutics
  • Cytori Therapeutics
  • MEDIPOST
  • Mesoblast
  • NuVasive
  • Osiris Therapeutics
  • Plasticell
  • Pluristem Therapeutics
  • Pfizer
  • StemCells Inc
  • STEMCELL Technologies
  • Takara Bio
  • Tigenix

第15章SWOT工業分析

  • 到目前為止,什麼因素增強了該行業?
  • 同種異體和自體幹細胞產業的SWOT分析
  • 該領域的主要驅動力是什麼?
  • 限制再生醫學產業整體的因素
  • 該行業的行業機會
  • 美國SWOT分析
    • 增長機會
    • 促進因素
    • 市場挑戰
  • 英國SWOT分析
  • 韓國SWOT分析
  • 中國SWOT分析
  • 日語SWOT分析
  • 新加坡S的SWOT分析
目錄
Product Code: 2020RM

This report provides a comprehensive overview of the size of the regenerative medicine market, segmentation of the market (stem cells, tissue engineering and CAR-T therapy), key players and the vast potential of therapies that are in clinical trials. Kelly Scientific analysis indicates that the global regenerative medicine market was worth $35 billion in 2019 and will grow to over $124 billion by 2025, with a CAGR of 23.3% between this time frame. Within this market, the stem cell industry will grow significantly at a CAGR of over x% and reach $x billion by 2025. Tissue engineering is forecast to grow at a CAGR of x% to 2025 and potentially reach $x billion.

This report describes the evolution of such a huge market in 15 chapters supported by over 350 tables and figures in 700 pages.

  • An overview of regenerative medicine that includes: stem cells, allogenic and autogenic cells, umbilical cord blood banking, tissue engineering and CAR T therapies.
  • Global regenerative medicine market, global breakdown, application breakdown and leading market players
  • Detailed account of the stem cell industry market by geography, indication and company profiles
  • Profiles, marketed/pipeline products, financial analysis and business strategy of the major companies in this space
  • Focus on current trends, business environment, pipeline products, clinical trials, and future market forecast for regenerative medicine
  • Insight into the challenges faced by stakeholders, particularly about the success vs. failure ratios in developing regenerative medicine drugs and therapies.
  • Insight into the biobanking industry globally and its impact on the overall market
  • Description and data for the prevalence of disease types that are addressed by regenerative medicine, stem cells, tissue engineering and CAR-T therapies
  • Financial market forecast through 2023 with CAGR values of all market segments outlined in the objective
  • SWOT analysis of the global market
  • Geographical analysis and challenges within key topographies including the USA, Japan, South Korea, China and Europe

Table of Contents

1.0 Report Synopsis

  • 1.1 Objectives of Report
  • 1.2 Executive Summary
  • 1.2 Key Questions Answered in this Report
  • 1.3 Data Sources and Methodology

2.0 Introduction

  • 2.1 Gurdon and Yamanaka Share the Nobel Prize
  • 2.2 Stem Cell Clinical Trials: Initiated in 2010
  • 2.3 Types of Stem Cells
  • 2.4 Adult (Tissue) Stem Cells
  • 2.5 Pluripotent Stem Cells
  • 2.6 Somatic Cell Nuclear Transfer (SCNT)
  • 2.7 Induced pluripotent Stem Cells (iPSC)
  • 2.8 Mesenchymal Cells
    • 2.8.1 MSCs in the Bone Marrow Stroma
    • 2.8.2 Isolation, Marker Specificity and Functional Properties of MSCs
    • 2.8.3 Oxygen Concentration and MSC Culture
    • 2.8.4 Assays to Define MSCs
    • 2.8.5 Differentiation Potential of MSCs
    • 2.8.6 Therapeutic Potential of MSCs
    • 2.8.7 Mesenchymal Stem Cells & Chronic Disease
    • 2.8.8 MSCs and Amylotrophic Lateral Sclerosis
    • 2.8.9 MSCs and Parkinson's Disease
    • 2.8.10 MSCs and Alzheimer Disease
    • 2.8.11 MSCs and Rheumatoid Arthritis
    • 2.8.12 MSCs and Type 1 Diabetes
    • 2.8.13 MSCs and Cardiovascular Disease
  • 2.9 Hematopoietic Stem and Progenitor Cells
    • 2.9.1 In Vivo Assays for Hematopoietic Stem Cells
    • 2.9.2 In Vitro Assays for Hematopoietic Stem and Progenitor Cells
    • 2.9.3 Isolation of Hematopoietic Stem and Progenitor Cells
    • 2.9.4 Culture of Hematopoietic Cells
    • 2.9.5 Therapeutic uses of Hematopoietic Cells
  • 2.10 Umbilical Cord Stem Cells
  • 2.11 Heart Stem Cells
    • 2.11.1 Cutting Edge Research in Heart Stem Cells
  • 2.12 Mammary Stem Cells
    • 2.12.1 Defining the Mammary Stem Cell
    • 2.12.2 Influence of Model System on Stem Cell Identification
    • 2.12.3 Breast Cancer Stem Cells
  • 2.13 Neural Stem Cells
    • 2.13.1 Identification of Neural Stem Cells
    • 2.13.2 Function of Neural Stem Cells in Vivo
    • 2.13.3 Neural Stem Cell Culture Systems
    • 2.13.4 Isolation Strategies for Neural Stem Cells
    • 2.13.5 Brain Tumour Stem Cells
    • 2.13.6 Cutting Edge Research in Neural Stem Cells
  • 2.14 Stem Cell Applications in Retinal Repair
    • 2.14.1 Embryonic Stem Cells as Retina Therapeutics
    • 2.14.2 Induced Pluripotent Stem Cells as Retina Therapeutics
    • 2.14.3 Adipose Derived Mesenchymal Stem Cells as Retina Therapeutics
  • 2.15 Liver Stem Cells
  • 2.16 Gut Stem Cells
  • 2.16 Pancreatic Stem Cells
  • 2.17 Epidermal Stem Cells

3.0 Stem Cells and Clinical Trials

  • 3.1 Introduction
  • 3.2 Pluripotent Stem Cells
  • 3.3 Limbal Stem Cells
  • 3.4 Neural Stem Cells
  • 3.5 Endothelial Stem or Progenitor Cells
  • 3.6 Placental Stem Cells
  • 3.7 Why Do Stem Cell Clinical Trials Fail?
  • 3.8 What is the Future of Stem Cell Trials?
  • 3.9 Cutting Edge Stem Cell Clinical Trials
  • 3.10 Ocata Therapeutics Current Stem Cell Trials
  • 3.11 CHA Biotech Current Stem Cell Trials
  • 3.12 Pfizer Current Stem Cell Trials
  • 3.13 GSK Current Stem Cell Trials
  • 3.14 Bayer Current Stem Cell Trials
  • 3.15 Mesoblast International Current Stem Cell Trials
  • 3.16 Millennium Pharmaceutical Current Stem Cell Trial
  • 3.17 AstraZeneca Current Stem Cell Trials
  • 3.18 Merck Current Stem Cell Trials
  • 3.19 Chimerix Current Stem Cell Trials
  • 3.20 Eisai Current Stem Cell Trials
  • 3.21 SanBio Current Stem Cell Trials
  • 3.22 Celgene Current Stem Cell Trials
  • 3.23 StemCells Current Stem Cell Trials
  • 3.24 Genzyme (Sanofi) Current Stem Cell Trials
  • 3.25 Teva Current Stem Cell Trials
  • 3.26 MedImmune Current Stem Cell Trials
  • 3.27 Janssen Current Stem Cell Trials
  • 3.28 Seattle Genetics Current Stem Cell Trials
  • 3.29 Baxter Healthcare Current Stem Cell Trials
  • 3.30 InCyte Corp Current Stem Cell Trials

4.0 Stem Cells, Disruptive Technology, Drug Discovery & Toxicity Testing

  • 4.1 Introduction
  • 4.2 Case Study: Genentech and Stem Cell Technology
  • 4.3 3D Sphere Culture Systems
  • 4.4 Stem Cells and High Throughput Screening
    • 4.4.1 Embryonic Stem Cells
    • 4.4.2 Adult Stem Cells
    • 4.4.3 Opportunities & Challenges
  • 4.5 Genetic Instability of Stem Cells
  • 4.6 Comprehensive in Vitro Proarrhythmia Assay (CiPA) & Cardiomyocytes
  • 4.8 Coupling Precise Genome Editing (PGE) and iPSCs
  • 4.9 Stem Cells & Toxicity Testing
    • 4.9.1 Hepatotoxicity and iPSCs
    • 4.9.2 Cardiotoxicity and iPSCs
    • 4.9.3 Neurotoxicity and iPSCs
  • 4.10 Stem Cell Disease Models
  • 4.11 Defining Human Disease Specific Phenotypes
    • 4.11.1 Molecular Phenotypes for Disease Modelling
    • 4.11.2 Cellular Phenotypes for Disease Modelling
    • 4.11.3 Physiological Phenotypes for Disease Modelling
    • 4.11.4 Parkinson's Disease
    • 4.11.5 Alzheimer's Disease
    • 4.11.6 Amyotrophic Lateral Sclerosis
    • 4.11.7 Huntington's Disease
    • 4.11.8 Spinal Muscular Atrophy
    • 4.11.9 Down Syndrome
    • 4.11.10 Cystic Fibrosis
    • 4.11.11 Colorectal Cancer
  • 4.12 Advantages of Stem Cell Derived Cells & Tissues for Drug Screening

5.0 Stem Cell Biomarkers

  • 5.1 Pluripotent Stem Cell Biomarkers
  • 5.2 Mesenchymal Stem Cell Biomarkers
  • 5.3 Neural Stem Cell Biomarkers
  • 5.4 Hematopoietic Stem Cell Biomarkers

6.0 Manufacturing Stem Cell Products

  • 6.1 Manufacturing Strategies For Stem Cell Products
  • 6.2 BioProcess Economics for Stem Cell Products
  • 6.3 Capital Investment
  • 6.4 Cost of Goods
  • 6.5 Bioprocess Economic Drivers & Strategies
  • 6.6 hPSC Expansion & Differentiation using Planar Technology
  • 6.7 hPSC Expansion using 3D Culture
  • 6.8 Microcarrier Systems
  • 6.9 Aggregate Suspension
  • 6.10 Bioreactor Based Differentiation Strategy
  • 6.11 Integrated hPSC Bioprocess Strategy
  • 6.12 GMP Regulations and Stem Cell Products

7.0 Investment & Funding

  • 7.1 What do Investors Want from Cell & Gene Therapy Companies?
  • 7.2 What Makes a Good Investment?
  • 7.3 What Types of Companies do Not Get Investment?
  • 7.4 Global Funding
  • 7.5 Cell & Gene Therapy Investment Going Forward
  • 7.6 What Cell & Gene Companies are the Most Promising in 2018?
  • 7.7 Insights into Investing in Cell and Gene Therapy Companies

8.0 Regenerative Medicine Market Analysis & Forecast to 2025

  • 8.1 Market Overview
  • 8.2 Global Frequency Analysis
  • 8.3 Economics of Regenerative Medicine
  • 8.4 Market Applications & Opportunities for Regenerative Therapies
    • 8.4.1 Neurological Disease
    • 8.4.2 Autoimmune Disorders
    • 8.4.3 Cardiovascular Disease
    • 8.4.4 Diabetes
    • 8.4.5 Musculoskeletal Disorders
    • 8.4.6 Ocular Disease
    • 8.4.7 Orthopedic Disorders
    • 8.4.8 Wound Healing
  • 8.5 Global Financial Landscape
  • 8.6 Regenerative Medicine Clinical Trial Statistics
  • 8.7 Regenerative Medicine Market Forecast to 2025
  • 8.8 Regenerative Medicine Geographic Analysis and Forecast to 2025
  • 8.9 Regenerative Medicine Geographical Location of Companies
  • 8.10 Regenerative Medicine Technology Breakdown of Companies
  • 8.11 Commercially Available Regenerative Medicine Products
  • 8.12 Major Regenerative Medicine Milestones

9.0 Stem Cell Market Analysis & Forecast to 2025

  • 9.1 Autologous & Allogenic Cell Market Analysis
  • 9.2 Stem Cell Market by Geography
    • 9.2.1 North America
    • 9.2.2 Asia/Pacific
    • 9.2.3 Europe
  • 9.3 Stem Cell Market Forecast by Therapeutic Indication
    • 9.3.1 Orthopedic/Musculoskeletal Stem Cell SubMarket
    • 9.3.2 Cancer Stem Cell SubMarket
    • 9.3.3 Cardiology/Vascular Stem Cell SubMarket Analysis
    • 9.3.4 Wound Healing Stem Cell SubMarket Analysis
    • 9.3.5 Skin Stem Cell SubMarket Analysis
    • 9.3.6 Ocular Stem Cell SubMarket Forecast
  • 9.4 Stem Cell Reagent Market Trends

10.0 Tissue Engineering Tissue Engineering Market Analysis and Forecast to 2025

  • 10.1 Geographical Analysis and Forecast to 2025
    • 10.1.1 North America
    • 10.1.2 Europe
    • 10.1.3 Asia Pacific
  • 10.2 Geographical Analysis by Company Share
  • 10.3 Tissue Engineering Clinical Indication Analysis & Forecast to 2025
    • 10.3.1 Orthopedic and Musculoskeletal
    • 10.3.2 Oncology
    • 10.3.3 Cardiology and Vascular
    • 10.3.4 Dermatology
    • 10.3.5 Oral and Dental

11.0 Biobanking Market Analysis

  • 11.1 Increasing Number of Cord Blood Banks Globally
  • 11.2 Global Biobanking Company Sector Analysis & Breakdown
  • 11.3 Allogenic Versus Autologous Transplant Frequency
  • 11.4 Biobanking Market Analysis & Forecast to 2025
  • 11.5 Major Global Players

12.0 Global Access & Challenges of the Regenerative Medicine Market

  • 12.1 Regenerative Medicine Market in the USA
  • 12.2 Regenerative Medicine in Japan
    • 12.2.1 Financial Investment
    • 12.2.2 Unconventional Company Investment in Regenerative Medicine
  • 12.3 Regenerative Medicine in China
  • 12.4 Regenerative Medicine in South Korea

13.0 Cell and CAR T Therapy

  • 13.1 Challenges Relating to Cell therapy and Chimeric Antigen Receptor T Cells in Immunotherapy
    • 13.1.1 Clinical Status of CD19 CAR-T Cells To Date
    • 13.1.2 Clinical and Regulatory Challenges for Development of CAR T Cells
    • 13.1.3 Key Regulatory Challenges Associated with CAR-T Development
    • 13.1.4 Summary of Select CAR-T Products by Juno, Novartis and Kite
    • 13.1.5 Clinical Benefit Versus Toxicity in CD19-Directed ALL Clinical Trials
    • 13.1.6 How to Manage Toxicity of CAR-T Therapy
  • 13.2 Regulations Pertaining to Immunotherapy, including Adoptive Cell Therapy (CAR-T and TCR) Immunotherapy Regulation in the USA
    • 13.2.1 Center for Biologics Evaluation and Research (CBER)
    • 13.2.2 Compliance and Surveillance
    • 13.2.3 Extra Resources on Immunotherapeutics from the FDA
    • 13.2.4 Cellular, Tissue and Gene Therapies Advisory Committee
    • 13.2.5 Consumer Affairs Branch (CBER) Contact in FDA
    • 13.2.6 FDA Regulations Pertaining to Immunotherapies
    • 13.2.7 Case Study Ovarian Cancer Immunotherapy Regulations
      • 13.2.7.1 Efficacy
      • 13.2.7.2 Adverse Effects
    • 13.2.8 Trial Design Considerations for Immunotherapy
    • 13.2.9 Development of Immune-Related Response Criteria (irRC) & Clinical Endpoints Specific to Immunotherapies
  • 13.3 Regulations for Cell Therapy & Immunotherapy in Japan
    • 13.3.1 PMDA and Cell Therapy & Immunotherapy
    • 13.3.2 Increasing the Efficiency in Cell Therapy & Immunotherapy Regulatory Review
    • 13.3.3 Forerunner Review Assignment System
    • 13.3.4 Revised Guidelines for Clinical Evaluation of Anti-Malignant Tumor Agents
    • 13.3.5 Key Contacts Within the PMDA for Cell Therapy & Immunotherapeutics
  • 13.4 European Regulation and Cell Therapy & Immunotherapeutics
    • 13.4.1 Introduction
    • 13.4.2 Challenges for Cell Therapy & Immunotherapy in EMEA
    • 13.4.3 EMA Status on Potency Testing
      • 13.4.3.1 In Vivo Potency Testing
      • 13.4.3.2 In Vitro Potency Testing
      • 13.4.3.3 Viable Cell Count
      • 13.4.3.4 Autologous Cell Based Products
      • 13.4.3.5 Reference Preparation
      • 13.4.3.6 Adjuvant Containing Immunotherapy Products
    • 13.4.4 EMA Status on Identifying hyper, Hypo or non-Responders
    • 13.4.5 Challenges Relating to Biomarkers in Immunotherapy
    • 13.4.6 Challenges Relating to Chimeric Antigen Receptor T Cells in Immunotherapy
    • 13.4.7 Estimating Optimal Cut-Off Parameters
    • 13.4.8 EU-Approved Immunotherapies in Melanoma
    • 13.4.9 Key Contacts Within EMA for Cell Therapy & Immunotherapeutics
  • 13.5 Manufacturing of Immunotherapies
    • 13.5.1 Introduction
    • 13.5.2 Generation of CAR-Modified T Cells
    • 13.5.3 What Co-Stimulation and Activity Domain is Optimal to Use?
    • 13.5.4 Optimizing Cell Culture Media
    • 13.5.5 Manufacturing Lentiviral Vectors
    • 13.5.6 Detection of Integrated CAR-Expressing Vectors
    • 13.5.7 Donor Lymphocyte Infusion Procedure
    • 13.5.8 Ex Vivo Costimulation & Expansion of Donor T Cells
    • 13.5.9 Infusion to the Patient
    • 13.5.10 Manufacturing Devices and Instruments Required for Immunotherapy Production
      • 13.5.10.1 Leukapheresis
      • 13.5.10.2 Cell Counters and Analyzer
      • 13.5.10.3 Cell Seeding, Growth and Propagation
    • 13.5.11 Good Manufacturing Procedure (GMP) for Immunotherapy
    • 13.5.12 Case Study Production of Lentivirus Induced Dendritic Cells under GMP Conditions
    • 13.5.13 Quality Control
    • 13.5.14 Regulatory Affairs
    • 13.5.15 Key Challenges in Manufacturing
      • 13.5.15.1 Electroporation of T-cells
      • 13.5.15.2 Allogenic CAR T cells
      • 13.5.15.3 Relapse Rates are Critical
      • 13.5.15.4 Antigen Negative Relapse
      • 13.5.15.5 Incorporating Suicide Genes
    • 13.5.16 Automation in Cell Therapy Manufacturing
    • 13.5.17 Autologous Cell Therapy Manufacture Scale Up
  • 13.6 Supply Chain & Logistics
    • 13.6.1 Introduction
    • 13.6.2 Case Study: Juno Therapeutics
  • 13.7 Pricing & Cost Analysis
    • 13.7.1 Introduction
    • 13.7.2 CAR T Therapy Market Evaluation
    • 13.7.3 Current Deals Within the CAR T Market
  • 13.8 CAR-T Therapy and Solid Tumors
    • 13.8.1 Challenges for Solid Tumors
      • 13.8.1.1 Off-Tumor Toxic Responses
      • 13.8.1.2 Poor Penetration to Tumor Site
      • 13.8.1.3 Increasing Therapeutic Efficiency
    • 13.8.2 Avoiding Immunosuppression within Tumor Microenvironment
    • 13.8.3 Clinical Trials Show Promise

14.0 Company Profiles

  • 14.1 Astellas Institute for Regenerative Medicine (Ocata Therapeutics)
    • 14.1.1 Company Background
    • 14.1.2 Products
    • 14.1.3 Financials
    • 14.1.4 Company Strategy
  • 14.2 Athersys
    • 14.2.1 Company Background
    • 14.2.2 Products
    • 14.2.3 Financial Analysis
    • 14.2.4 Company Strategy
  • 14.3 Baxter International (Baxalta, Shire)
    • 14.3.1 Company Background
    • 14.3.2 Financial Analysis
    • 14.3.3 Company Strategy
  • 14.4 Caladrius Biosciences (NeoStem)
    • 14.4.1 Company Details
    • 14.4.2 Products
      • 14.4.2.1 CLBS20
      • 14.4.2.2 CLBS03 Treg Cellular Therapy
      • 14.4.2.3 CLBS12 CD34 Cell Therapy
    • 14.4.3 Financial Analysis
    • 14.4.4 Company Strategy
  • 14.5 Cynata Therapeutics
    • 14.5.1 Company Background
    • 14.5.2 Product Details
    • 14.5.3 Financial Data
    • 14.5.4 Company Strategy
  • 14.6 Cytori Therapeutics
    • 14.6.1 Company Products
    • 14.6.2 Financial Analysis
    • 14.6.3 Company Strategy
  • 14.7 MEDIPOST
    • 14.7.1 Company Details
    • 14.7.2 Company Products
      • 14.7.2.1 CellTree Umbilical Cord Blood Bank
      • 14.7.2.2 CARTISTEM®
      • 14.7.2.3 NEUROSTEM®
      • 14.7.2.4 PNEUMOSTEM ®
    • 14.7.3 Financial Analysis
  • 14.8 Mesoblast
    • 14.8.1 Company Details
      • 14.8.1.1 Unique Features of Mesoblast and its Disruptive Technology
      • 14.8.1.2 Allogeneic Mesenchymal Lineage Adult Stem Cells (MLCs)
      • 14.8.1.3 Mechanism of Action of MLC Products
      • 14.8.1.4 Manufacturing of Mesoblast MLC-Based Products
      • 14.8.1.5 Mesoblast Patent Portfolio
    • 14.8.2 Mesoblast Product Portfolio
      • 14.8.2.1 MSC-100-IV/TEMCELL® for Acute Graft Versus Host Disease (aGVHD)
      • 14.8.2.2 MPC-150-IM - Chronic Heart Failure (CHF)
      • 14.8.2.3 MPC-25-IC for Acute Myocardial Infarction
      • 14.8.2.4 MPC-06-ID - Chronic Low Back Pain (CLBP) due to Degenerative Disc Disease (DDD)
      • 14.8.2.5 MPC-300-IV for Biologic-Refractory Rheumatoid Arthritis
      • 14.8.2.6 MPC-300-IV for Diabetic Nephropathy
      • 14.8.2.7 MPC-100-IV for Crohn's Disease
      • 14.8.2.8 MPC-25-Osteo for Spinal Fusion
    • 14.8.3 Mesoblast International Strategic Business Collaborations
    • 14.8.4 Mesoblast Financial Analysis
  • 14.9 NuVasive
    • 14.9.1 Company Details
    • 14.9.2 Biologic Products for the Spinal Surgery Market
      • 14.9.2.1 Formagraft
      • 14.9.2.2 AttraX
      • 14.9.2.3 Propel DBM
      • 14.9.2.4 Osteocel Plus and Pro
    • 14.9.3 Financial Analysis
    • 14.9.4 Company Business Strategy
  • 14.10 Osiris Therapeutics
    • 14.10.1 Company Profile
      • 14.10.1.1 BioSmart Cryopreservation Technology
      • 14.10.1.2 MSC Primer Technology
    • 14.10.2 Products
      • 14.10.2.1 Grafix
      • 14.10.2.2 BIO 4
      • 14.10.2.3 Cartiform
      • 14.10.2.4 Stravix
    • 14.10.3 Company Financial Analysis
    • 14.10.4 Company Strategy
  • 14.11 Plasticell
    • 14.11.1 Company Profile
  • 14.12 Pluristem Therapeutics
    • 14.12.1 Company Profile
    • 14.12.2 Products
      • 14.12.2.1 PLacental eXpanded (PLX) Cells
      • 14.12.2.2 PLX-PAD
      • 14.12.2.3 PLX-R18
    • 14.12.3 Financial Analysis
    • 14.12.4 Business Strategy
  • 14.13 Pfizer
    • 14.13.1 Company Profile
  • 14.14 StemCells Inc
    • 14.14.1 Company Profile
    • 14.14.2 HuCNS-SC Platform Technology
    • 14.14.3 Clinical Trial Analysis
    • 14.14.4 Financial Analysis
  • 14.15 STEMCELL Technologies
    • 14.15.1 Company Details
    • 14.15.2 Product Details
  • 14.16 Takara Bio
    • 14.16.1 Company Details
    • 14.16.2 Product Portfolio
      • 14.16.2.1 HF10 Anti-Cancer Therapy
      • 14.16.2.2 TCR Gene Therapy
      • 14.16.2.3 MazF Gene Therapy
    • 14.16.3 Centre for Cell and Gene Processing
    • 14.16.4 Company Financials
    • 14.16.5 Company Strategy
  • 14.17 Tigenix
    • 14.17.1 Company Background
    • 14.17.2 Products
    • 14.17.3 Financial Data
    • 14.17.4 Company Strategy

15.0 SWOT Industry Analysis

  • 15.1 What has Strengthened the Industry Thus Far?
  • 15.2 Allogenic and Autologous Stem Cell Industry SWOT Analysis
  • 15.3 What are the Main Driving Forces of this Space?
  • 15.4 Restraints of the Regenerative Medicine Industry as a Whole
  • 15.5 Industry Opportunities Within this Sector
  • 15.6 USA SWOT Analysis
    • 15.6.1 Growth Opportunities
    • 15.6.2 Drivers
    • 15.6.3 Market Challenges
  • 15.7 UK SWOT Analysis
    • 15.7.1 Growth Opportunities
    • 15.7.2 Drivers
    • 15.7.3 Market Challenges
  • 15.8 South Korea SWOT Analysis
    • 15.8.1 Growth Opportunities
    • 15.8.2 Drivers
    • 15.8.3 Market Challenges
  • 15.9 China SWOT Analysis
    • 15.9.1 Growth Opportunities
    • 15.9.2 Drivers
    • 15.9.3 Challenges
  • 15.10 Japan SWOT Analysis
    • 15.10.1 Opportunities
    • 15.10.2 Market Drivers
    • 15.10.3 Challenges
  • 15.11 Singapore SWOT Analysis
    • 15.11.1 Opportunities
    • 15.11.2 Market Drivers
    • 15.11.3 Challenges

List of Exhibits

  • Exhibit 2.1 Stem Cell Discovery and Development Timeline
  • Exhibit 2.2 Potential Therapeutic Uses of Stem Cells
  • Exhibit 2.3 Embryonic Stem Cell Differentiation
  • Exhibit 2.4 Pluripotent Stem Cells
  • Exhibit 2.5 Clinical Uses of Stem Cells
  • Exhibit 2.6 Illustration of Inner Cell Mass Generation for Stem Cell Culture
  • Exhibit 2.7 Drug Development Strategies for Patient Derived iPSCs
  • Exhibit 2.8 Mesenchymal Stem Cell Lineage Progression & Differentiation
  • Exhibit 2.9 Mesenchymal Stem Cell Differentiation
  • Exhibit 2.10 Potential Therapeutic Effects of MSCs
  • Exhibit 2.11 Hematopoietic Stem Cells & the Formation of Mature Blood Cells
  • Exhibit 2.12 Donor Types for HSC transplantation
  • Exhibit 2.13 Total Number of Stem Cell Donors 1989-Present
  • Exhibit 2.14 Cross Section of Umbilical Cord Sample for Stem Cell Extraction
  • Exhibit 2.15 Umbilical Cord Blood and Wharton's Jelly; Sources of HSCs and MSCs
  • Exhibit 2.16 Comprehensive List of Conditions Treated by Cord Blood Transplants
  • Exhibit 2.17 Cardiac Progenator Cell Populations
  • Exhibit 2.18 Transplanted Cardiac Progenitor Cells: Potential Mechanism of Action in the Myocardium
  • Exhibit 2.19 Mammary Stem Cells in the Presence and Absence of Hormones
  • Exhibit 2.20 Mammary Stem Cell Tree Following Transplantation
  • Exhibit 2.21 Production of Neurons, Astrocytes and Oligodendrocytes from Neural Stem Cells
  • Exhibit 2.22 Physiology of the Eye
  • Exhibit 2.23 Physiological Functions of Each Eye Component
  • Exhibit 2.24 Healthy & Degenerated Retinal Pigment Epithelium
  • Exhibit 2.25 Human Embryonic Stem Cell-Derived Retinal Pigment Epithelium
  • Exhibit 2.26 Using Stem Cells to Replace Dysfunctional Retinal Pigment Epithelial Cells
  • Exhibit 2.27 Using Stem Cells to Replace Retinal Nerve Cells
  • Exhibit 2.28 Stem Cells Located Around the Central Vein in the Liver
  • Exhibit 2.29 Gut Stem Cells are Located in the Crypts of Lieberhahn
  • Exhibit 2.30 Localization of Epidermal & Dermal Stem Cells
  • Exhibit 3.1 Current Therapeutic Areas and Disease States with Number of Stem Cell Clinical Trials, Globally
  • Exhibit 3.2 Current Geographical Location and Number of Stem Cell Clinical Trials, Globally
  • Exhibit 3.3 Current Geographical Location and Number of Stem Cell Clinical Trials, USA
  • Exhibit 3.4 Current Geographical Location and Number of Stem Cell Clinical Trials, Europe
  • Exhibit 3.5 Current Geographical Location and Number of Stem Cell Clinical Trials, East Asia
  • Exhibit 3.6 Select hESC and iPSC-Based Products in Clinical Trials by Disease, Stage and Trial Status
  • Exhibit 3.7 Selected Studies and Key Findings of PSC-Based Therapies in Development for AMD, Diabetes, Liver Disease, Parkinson's and Thalassemia
  • Exhibit 3.8 Ocata Therapeutics Current Stem Cell Trials, Globally
  • Exhibit 3.9 CHA Biotech Current Stem Cell Trials, Globally
  • Exhibit 3.10 Pfizer Current Stem Cell Trials, Globally
  • Exhibit 3.11 GSK Current Stem Cell Trials, Globally
  • Exhibit 3.12 Bayer Current Stem Cell Trials, Globally
  • Exhbit 3.13 Mesoblast International Current Stem Cell Trials, Globally
  • Exhibit 3.14 Millennium Pharmaceutical Current Stem Cell Trials, Globally
  • Exhibit 3.15 AstraZeneca Current Stem Cell Trials, Globally
  • Exhibit 3.16 Merck Current Stem Cell Trials, Globally
  • Exhibit 3.17 Chimerix Current Stem Cell Trials, Globally
  • Exhibit 3.18 Eisai Current Stem Cell Trials, Globally
  • Exhibit 3.19 SanBio Current Stem Cell Trials, Globally
  • Exhibit 3.20 Celgene Current Stem Cell Trials, Globally
  • Exhibit 3.21 StemCells Current Stem Cell Trials, Globally
  • Exhibit 3.22 Genzyme (Sanofi) Current Stem Cell Trials, Globally
  • Exhibit 3.23 Teva Current Stem Cell Trials, Globally
  • Exhibit 3.24 MedImmune Current Stem Cell Trials, Globally
  • Exhibit 3.25 Janssen Current Stem Cell Trials, Globally
  • Exhibit 3.26 Seattle Genetics Current Stem Cell Trials, Globally
  • Exhibit 3.27 Baxter Healthcare Current Stem Cell Trials, Globally
  • Exhibit 3.28 InCyte Corp Current Stem Cell Trials, Globally
  • Exhibit 4.1 Disease Models Generated from iSPC using Genome Editing
  • Exhibit 4.2 Stem Cells Used for Drug Screening
  • Exhibit 4.3 Sucessful Human iPSC Mediate Therapy Cases
  • Exhibit 4.4 Number of US Patients That Could Benefit From Stem Cell Therapeutics
  • Exhibit 4.5 Genentechs Stem Cell Platform for Drug & Toxicity Screening
  • Exhibit 4.6 Key Challenges in Assessing Genetic Instability of Stem Cells
  • Exhibit 4.7 Comprehensive In Vitro Proarrhythmia Assay (CiPA) Components
  • Exhibit 4.8 Ex Vivo Gene Therapy and Stem Cell Technology
  • Exhibit 4.9 Genome Editing and iPSCs
  • Exhibit 4.10 Gene Edited iPSC/hES-Mediated Novel Therapy Development
  • Exhibit 4.11 Comparison of 3D and 2D Cultures of iPSC-Derived Hepatocytes Following Treatment with Toxins, Anti-Proliferative Agents and Other Drugs
  • Exhibit 4.12 Potential Applications of Human iPSCs for Liver Diseases
  • Exhibit 4.13 Myocardial Tissue: Cardiomyocytes, Endothelial Cells and Fibroblasts
  • Exhibit 4.14 Cardiovascular Disease-Specific Human Pluripotent Stem Cell Lines by Genetic Cause and Drug Testing
  • Exhibit 4.15 Culture of Human iPSC-Derived Dopaminergic Neurons over 14 Days
  • Exhibit 4.16 Strategies for Generating Disease Models Using Human Pluripotent Stem Cells (PSCs)
  • Exhibit 4.17 Criteria for Disease Modelling Using Pluripotent Stem Cells
  • Exhibit 4.18 Models of Monogenic Dominant Diseases
  • Exhibit 4.19 Models of Monogenic Recessive Diseases
  • Exhibit 4.20 Models of Monogenic X-linked Recessive Diseases
  • Exhibit 4.21 iPSCs in Neurological Disease Modeling, Drug Screening & Cell Therapy
  • Exhibit 4.22 Advantages and Uses of Intestinal Organoids
  • Exhibit 5.1: Main Biomarkers Associated with Pluripotent Stem Cells
  • Exhibit 5.2: Pluripotent Stem Cell Biomarkers
  • Exhibit 5.3 Main Biomarkers Associated with Mesenchymal Stem Cells
  • Exhibit 5.4 Mesenchymal Stem Cell Biomarkers
  • Exhibit 5.5 Main Biomarkers Associated with Neural Stem Cells
  • Exhibit 5.6 Neural Stem Cell Biomarkers
  • Exhibit 5.7 Main Biomarkers Associated with Hematopoietic Stem Cells
  • Exhibit 5.8 Hematopoietic Stem Cell Biomarkers
  • Exhibit 6.1 Bioprocess Development Considerations for hPSC-Derived Products
  • Exhibit 6.2 Technologies Used for Expansion & Differentiation of hPSC-Derived Cell Products
  • Exhibit 6.3 Comparison of Key Performance Characteristics of Cardiomyocytes, Hepatocytes, Neurons, Neural Progenitor Cells, Endoderm Progenitors and Hepatocytes in Planar & Bioreactor Based Differentiation Protocols
  • Exhibit 6.4 Integrated Expansion & Differentiation of hPSCs Studies by Cell, Process, Cell Density, Process Time and Target Cells Produced
  • Exhibit 6.5 hPSC Bioprocess Strategies, Planar, Segregated 3D & Integrated: Advantages & Disadvantages
  • Exhibit 6.6 Main Objectives of GMP Manufacturing
  • Exhibit 6.7 GMP Facilities Required for Stem Cell Product Manufacuring
  • Exhibit 6.8 Manufacturing Overview of hIPSCs under GMP Regulation
  • Exhibit 6.9 Key Steps in Manufacturing GMP Regulated iPSCs
  • Exhibit 6.10 Characterization and Release Assays for Human iPSCs Manufactured under GMP Conditions
  • Exhibit 6.11 MCB Viral Assays for use on Human iPSCs Bank
  • Exhibit 6.12 Differences Between Autologous & Allogeneic Cell Therapy Models
  • Exhibit 7.1 Selected Venrock Biotech and Healthcare Exits
  • Exhibit 7.2 Stem Cell Funding Bodies, Globally
  • Exhibit 7.3 Stem Cell Societies and Consortiums by Geography
  • Exhibit 7.4 Total Stem Cell NIH Funding 2014-2017
  • Exhibit 7.5 NIH Funded Stem Cell Related Projects 2014-2017
  • Exhibit 7.6 Tabular Data NIH Funded Stem Cell Related Projects 2014-2017
  • Exhibit 7.7 CIRM Investment Funding by Stem Cell Type
  • Exhibit 7.8 CIRM Stem Cell Project Investment Funding by Therapeutic Area
  • Exhibit 7.9 Promising Cell & Gene Companies
  • Exhibit 8.1 Global Frequency Indicator Trend of Terms Regenerative Medicine, Cell Therapy and Tissue Engineering, 2007-2017
  • Exhibit 8.2 GeoMap Frequency Indicator Trend of Terms Regenerative Medicine, Cell Therapy and Tissue Engineering, 2007-2017
  • Exhibit 8.3 Increased Proportion of People Over 65 Through 2050
  • Exhibit 8.4 Percentage of Global Population Aged 65 Plus 2015-2050
  • Exhibit 8.5 Global Alzheimer's Disease Market Forecast
  • Exhibit 8.6 Global Cardiovascular Market Forecast
  • Exhibit 8.7 Global Diabetes Therapy and Device Market Forecast
  • Exhibit 8.8 Bone Graft Global Market Forecast
  • Exhibit 8.9 Bone Graft Global Market Forecast by Geography
  • Exhibit 8.10 Total Global Financings of the Regenerative Medicine, Cell and Gene Therapy and Tissue Engineering Sector
  • Exhibit 8.11 Total Global Financing of Regenerative Medicine & Cellular/Gene Therapy by Type
  • Exhibit 8.12 Number of Global Clinical Trials by Phase of Regenerative Medicine, Cell and Gene Therapy Studies
  • Exhibit 8.13 Number of Global Clinical Trials by Indication of Regenerative Medicine, Cellular & Gene Therapeutics
  • Exhibit 8.14 Major Clinical Trial Events in Regenerative Medicine
  • Exhibit 8.15 Global Regenerative Medicine Market Value Tabular Forecast to 2025
  • Exhibit 8.16 Global Regenerative Medicine Market Value Forecast to 2025
  • Exhibit 8.17 Regenerative Medicine Geographic Analysis and Forecast to 2025
  • Exhibit 8.18 Regenerative Medicine Geographic Forecast Table to 2025
  • Exhibit 8.19 Regenerative Medicine Market Share by Geography 2019
  • Exhibit 8.20 Regenerative Medicine Market Share Forecast by Geography 2025
  • Exhibit 8.21 North America Regenerative Medicine Forecast to 2025
  • Exhibit 8.22 European Regenerative Medicine Forecast to 2025
  • Exhibit 8.23 Asia Pacific Regenerative Medicine Forecast to 2025
  • Exhibit 8.24 RoW Regenerative Medicine Forecast to 2025
  • Exhibit 8.25 Geographical Location of Regenerative Medicine Companies
  • Exhibit 8.26 Regenerative Medicine Technology Breakdown of Companies
  • Exhibit 8.27 Number and Geographical Location of Regenerative Medicine, Cellular Therapy & Gene Therapy Companies, Globally
  • Exhibit 8.28 Select FDA-Approved Regenerative Medicine Products by Biologics. Cell Based and Biopharmaceuticals
  • Exhibit 8.29 Regulatory Approved & Commercialized Regenerative Medicine Products Currently on the Market
  • Exhibit 8.30 Major Regenerative Medicine Milestones
  • Exhibit 9.1 Global Stem Cell Therapy Market Forecast Table to 2025
  • Exhibit 9.2 Global Stem Cell Therapy Market Forecast to 2025
  • Exhibit 9.3 Stem Cell Market Share by Adult and Embryonic Stem Cells and Stem Cell Banking
  • Exhibit 9.4 Major Clinical Trial Events in Stem Cell Medicine
  • Exhibit 9.5 Stem Cell Geographic Market Share Forecast to 2025
  • Exhibit 9.6 Global Stem Cell Market Share by Geographic Region 2019
  • Exhibit 9.7 Global Stem Cell Market Share by Geographic Region 2025
  • Exhibit 9.8 North American Stem Cell Market Forecast to 2025
  • Exhibit 9.9 Asia Pacific Stem Cell Market Forecast to 2025
  • Exhibit 9.10 European Stem Cell Market Forecast to 2025
  • Exhibit 9.11 Rest of the World Stem Cell Market Forecast to 2025
  • Exhibit 9.12 Market Share of Top Therapeutic Indications in Stem Cell Space, 2019
  • Exhibit 9.13 Market Share of Top Therapeutic Indications in Stem Cell Space, 2025
  • Exhibit 9.14 Stem Cell Market Forecast by Therapeutic Indications to 2025
  • Exhibit 9.15 Orthopedic/Musculoskeletal Stem Cell SubMarket Forecast to 2025
  • Exhibit 9.16 Cancer Stem Cell SubMarket Forecast to 2025
  • Exhibit 9.17 Cardiology/Vascular Stem Cell SubMarket Forecast to 2025
  • Exhibit 9.18 Wound Healing Stem Cell SubMarket Forecast to 2025
  • Exhibit 9.19 Skin Stem Cell Products and Sources
  • Exhibit 9.20 Skin Stem Cell SubMarket Forecast to 2025
  • Exhibit 9.21 Ocular Stem Cell SubMarket Forecast to 2025
  • Exhibit 9.22 Current Top Brands Being Used for Stem Cell R&D
  • Exhibit 9.23 Most Frequent Method of Obtaining Stem Cell Lines in R&D
  • Exhibit 9.24 Percentage of Stem Cell Characterization Analysis Kits Used in R&D
  • Exhibit 9.25 Percentage of Stem Cell Differentiation Kits Used in R&D
  • Exhibit 9.26 Most Common Types of Stem Cells Used in R&D by Mouse, Human & Rat Origin
  • Exhibit 10.1 Global Tissue Engineering Market Tabular Forecast to 2025
  • Exhibit 10.2 Global Tissue Engineering Market Forecast to 2025
  • Exhibit 10.3 Global Tissue Engineering Market Forecast by Geographic Region to 2025
  • Exhibit 10.4 North America Tissue Engineering Market Forecast to 2025
  • Exhibit 10.5 Europe Tissue Engineering Market Forecast to 2025
  • Exhibit 10.6 Asia Pacific Tissue Engineering Market Forecast to 2025
  • Exhibit 10.7 Geographical Breakdown of Tissue Engineering Companies Globally
  • Exhibit 10.8 Public and Privately Held Tissue Engineering Company Distribution, Globally
  • Exhibit 10.9 Main Players in the Tissue Engineering Market
  • Exhibit 10.10 Main Players in the CAR-T Market
  • Exhibit 10.11 Main Players in the TCR Market
  • Exhibit 10.12 Main Players in the NK Cell Market
  • Exhibit 10.13 Main Players in the TILs Market
  • Exhibit 10.14 Global Tissue Engineering Submarket Breakdown by Market Share 2019
  • Exhibit 10.15 Global Tissue Engineering Submarket Breakdown by Market Share Forecast 2025
  • Exhibit 10.16 Tissue Engineering Submarket Breakdown Forecast Table to 2025
  • Exhibit 10.17 Tissue Engineering Submarket Breakdown Forecast to 2025
  • Exhibit 10.18 Orthopedics/Musculoskeletal Tissue Engineering Market Forecast to 2025
  • Exhibit 10.19 Oncology Tissue Engineering Market Forecast to 2025
  • Exhibit 10.20 Cardiology and Vascular Tissue Engineering Market Forecast to 2025
  • Exhibit 10.21 Dermatology Tissue Engineering Market Forecast to 2025
  • Exhibit 10.22 Oral and Dental Tissue Engineering Market Forecast to 2025
  • Exhibit 11.1 Number of Stem Cell Donors by Geographical Location
  • Exhibit 11.2 Number and Geographical Location of Global Unrelated Cord Blood Units
  • Exhibit 11.3 Market Share of Companies in the BioBanking Industry
  • Exhibit 11.4 Market Share within Therapeutic Companies in the BioBanking Industry
  • Exhibit 11.5 Market Share within Cell & Tissue Banks in the BioBanking Industry
  • Exhibit 11.6 Percentage of Allogenic & Autologous Transplantations
  • Exhibit 11.7 Percentage Breakdown of Indications using Autologous Umbilical Cord Blood Transplants
  • Exhibit 11.8 Percentage Breakdown of Indications using Allogenic Umbilical Cord Blood Transplants
  • Exhibit 11.9 Global Cord Blood Banking Market Forecast to 2025
  • Exhibit 11.10 Stem Cell Biobanking Market Segments
  • Exhibit 11.11 Top Global Cord Blood and Tissue Companies
  • Exhibit 11.12 Important Players in the International Private Cord Bank Market
  • Exhibit 12.1 Key Challenges to the Regenerative Medicine & Cellular/Gene Therapy Market
  • Exhibit 12.2 Company and Indication that will Benefit from New 21st Century Cures Act, USA
  • Exhibit 12.3 Cell and Gene Based Therapy in Japan as Defined by the PMDA
  • Exhibit 12.4 Regulatory System in Japan for Regenerative Medicine and Cell and Gene Therapy Products
  • Exhibit 12.5 Main Stem Cell Research Institutes in China
  • Exhibit 13.1 Selected CD19-directed Product Candidates in Clinical Trials by Costimulatory & Binding Domains, Starting Cell Population, Vector and Ablation Technology
  • Exhibit 13.2 Select CD19-Directed ALL Clinical Trials
  • Exhibit 13.3 Select Anti-CD22 CAR-T Clinical Projects
  • Exhibit 13.4 CBER Compliance and Surveillance Activities
  • Exhibit 13.5 Contacts for the Cellular, Tissue and Gene Therapies Advisory Committee, FDA
  • Exhibit 13.6 Clinical Regulatory Pathway - Conventional Route
  • Exhibit 13.7 Clinical Regulatory Pathway - Option for Rapid Translation
  • Exhibit 13.8 PMDA Total Review Period of Standard Drugs
  • Exhibit 13.9 PMDA Total Review Period of Priority Drugs
  • Exhibit 13.10 Number of Approved Recombinant Protein Products by PMDA
  • Exhibit 13.11 Forerunner Review Assignment System Timeframe
  • Exhibit 13.12 Adaptive Licensing and Accelerated Approval in Japan-US-EU
  • Exhibit 13.13 Key Contacts Within PMDA, Japan
  • Exhibit 13.14 CheckMate 066 Clinical Trial
  • Exhibit 13.15 CheckMate 037 Clinical Trial
  • Exhibit 13.16 Contact Details for EMA Cell Therapy & Immunotherapy Experts
  • Exhibit 13.17 Method of Generating CAR-Modified T Cells
  • Exhibit 13.18 Clinical Activity, Cost Structure and Patient Convenience Flow Chart of CAR-T Therapy
  • Exhibit 13.19 General Technical and Personnel Requirements of a GMP, QC, QA, FDA Regulated Cell Therapy Manufacturing Facility
  • Exhibit 13.20 Technician/Scientific Requirements for CAR T Manufacturing
  • Exhibit 13.21 Selection of Apheresis Instruments Currently on the Market
  • Exhibit 13.22 Selection of Cell Counters and Analyzer Instruments Currently on the Market
  • Exhibit 13.23 Main Objectives of GMP Manufacturing Immunotherapeutics
  • Exhibit 13.24 Main Objectives of Quality Control While Manufacturing Immunotherapeutics
  • Exhibit 13.25 Main Objectives of Regulatory Affairs During Manufacturing Immunotherapeutics
  • Exhibit 13.26 CAR-T Studies Using mRNA Transfection Electroporation
  • Exhibit 13.27 Allogenic Versus Autologous Cell Manufacturing
  • Exhibit 13.28 Challenges for Autologous Cell Therapy Manufacture
  • Exhibit 13.29 Current Company/Institutions with Suicide Gene CAR T Projects
  • Exhibit 13.30 Advantages of Using Automated Cell Therapy Manufacturing
  • Exhibit 13.31 Main Drivers to Implement Automated Cell Therapy Manufacturing
  • Exhibit 13.32 Main Benefits of Automated Cell Therapy Manufacturing
  • Exhibit 13.33 Advantages & Disadvantages of Autologous Cell Therapy Manufacture Scale Up
  • Exhibit 13.34 Streptamer® -Based Magnetic Bead Cell Isolation Exhibit 13.35 Juno Therapeutics Manufacturing Facility Objectives
  • Exhibit 13.36 Annual Cost of Patented Cancer Therapeutics from 2000 to Today
  • Exhibit 13.37 Cost of Nivolumab, Pembrolizumab & Ipilimumab per mg
  • Exhibit 13.38 Current Juno Therapeutics Trials and CAR T Products
  • Exhibit 13.39 Current CAR T Business Deals
  • Exhibit 13.40 Selected Antigens, Endomains and Gene Transfer Methods Used for CAR-T Therapy
  • Exhibit 13.41 Immunosuppressive Modulators in Tumor Microenvironment
  • Exhibit 13.42 Challenges for CAR-T therapy and Solid Tumors
  • Exhibit 13.43 Tumor Associated Antigens for CART Therapy by Tissue Type
  • Exhibit 13.44 Select Clinical Trials using CAR-T in Solid Tumors
  • Exhibit 14.1 MultiStem Platform in Action
  • Exhibit 14.2 Key Advantages of MultiStem
  • Exhibit 14.3 Athersys Product and Clinical Pipeline
  • Exhibit 14.4 Athersys Key Business Strategies
  • Exhibit 14.5 Baxter International Product Revenue by Class
  • Exhibit 14.6 Baxter International Product Revenue by Geography
  • Exhibit 14.7 Baxter International Breakdown of Product Revenue
  • Exhibit 14.8 Caladrius Expertise in Cell Type and Therapeutic Application Portfolio
  • Exhibit 14.9 PCT Caladrius CLBS03 Treg Cellular Therapy Manufacturing Process
  • Exhibit 14.10 Caladrius Revenue
  • Exhibit 14.11 Caladrius Clinical Manufacturing Revenue
  • Exhibit 14.12 Caladrius Process Development Revenue
  • Exhibit 14.13 Cytori Cell Therapy Mechanism of Action in Angiogenesis, Inflammation and Wound Remodeling
  • Exhibit 14.14 Cytori Therapeutics Cell Therapy Clinical Pipeline
  • Exhibit 14.15 MediPost Product Pipeline by Indication and Clinical Study Phase
  • Exhibit 14.16 Medipost Sales Figures
  • Exhibit 14.17 CellTree Umbilical Cord Blood Bank Program Details and Pricing
  • Exhibit 14.18 Medipost Revenue Share by Product Category
  • Exhibit 14.19 Medipost Sales Revenue by Product Category
  • Exhibit 14.20 Medipost Umbilical Cord Blood Bank Revenue
  • Exhibit 14.21 Medipost Stem Cell Drug Sales Revenue
  • Exhibit 14.22 Medipost R&D Investment
  • Exhibit 14.23 Mesenchymal Lineage Adult Stem Cells (MLCs) Secrete a Variety of Immunomodulatory Molecules
  • Exhibit 14.24 Mesoblast Mesenchymal Lineage Adult Stem Cell (MLC) Functional Properties
  • Exhibit 14.25 Mesoblast Expanion and Immune Privilege of MLC Technology
  • Exhibit 14.26 Mesoblast Complementary Technology Platforms
  • Exhibit 14.27 Mechanism of Action of MPC-150-IM, MPC-06-ID, MPC-300-IV, TEMCELL(R)HS. Inj. and MSC-100-IV and MPC-25-OSTEO
  • Exhibit 14.28 Mesoblast MLC-Based Product Manufacturing and Distribution Process
  • Exhibit 14.29 Mesoblast Patent Portfolio with Expiration and Validity through 2035
  • Exhibit 14.30 Mesoblast Tier 1 and Tier 2 Product Candidates by Program and Clinical Stage
  • Exhibit 14.31 Mesoblast Lead Product MSC-100-IV/TEMCELL HS Inj
  • Exhibit 14.32 MSC-100-IV Treatment in Children with SR-aGVHD who Failed Other Modalities
  • Exhibit 14.33 MPC-300-IV for Treatment of Chronic Inflammatory Diseases
  • Exhibit 14.34 Mesoblast International Strategic Business Collaborations
  • Exhibit 14.35 Mesoblast Share Price and Financial Analysis
  • Exhibit 14.36 Mesoblast Revenue Generated
  • Exhibit 14.37 Mesoblast R&D Expenditure
  • Exhibit 14.38 NuVasive Biologics Portfolio
  • Exhibit 14.39 NuVasive Global Revenue
  • Exhibit 14.40 NuVasive NON GAAP Operating Profit Margin
  • Exhibit 14.41 NuVasive Spinal Surgery Product and Biologic Revenue Breakdown
  • Exhibit 14.42 NuVasive USA and International Revenue Breakdown
  • Exhibit 14.43 NuVasive Corporate Strategy Going Forward
  • Exhibit 14.44 Osiris Therapeutics Current Product Portfolio
  • Exhibit 14.45 Osiris Therapeutics Product Pipeline by Indication, Preclinical, Clinical and Market Stage
  • Exhibit 14.46 Exhibit Plasticel Partnerships and Collaborations with Industry and Academic Institutions
  • Exhibit 14.47 Pluristem Therapeutics Company Pipeline Portfolio by Product, Indication, Location & Phase
  • Exhibit 14.48 Pluristem Therapeutics Production of PLX-PAD & PLX-R18
  • Exhibit 14.49 Pluristem Therapeutics Revenue
  • Exhibit 14.50 Pluristem Therapeutics R&D Costs
  • Exhibit 14.51 Pfizer Stem Cell Policy
  • Exhibit 14.52 StemCell Inc Manufacturing Steps of Hu-CNS-SC Product
  • Exhibit 14.53 STEMCELL Technologies Product Portfolio
  • Exhibit 14.54 STEMCELL Technologies Brand Portfolio
  • Exhibit 14.55 Takara Bio Sales Revenue
  • Exhibit 14.56 Takara Bio Operating Sales
  • Exhibit 14.57 Takara BioIndustry Sales Revenue
  • Exhibit 14.58 Takara Bio Sales by Geographic Region
  • Exhibit 14.59 Tigenix Key Intellectual Property Patent Portfolio
  • Exhibit 14.60 Comprehensive List of Companies in the Stem Cell & Regenerative Medicine Industry
  • Exhibit 15.1 Advantages, Weaknesses, Opportunities & Threats of Allogenic & Autologous Stem Cells
  • Exhibit 15.2 Opportunistic Therapeutic Indications as Decided by Senior Key Opinion Leaders